Aurobindo Pharma's subsidiary CuraTeQ Biologics received CDSCO marketing authorisation for Bevqolva®, a bevacizumab biosimilar.
The approval covers manufacture at CuraTeQ's Hyderabad facility and marketing in 100mg/4mL and 400mg/16mL vial presentations.
Bevqolva® is indicated for metastatic carcinoma of the colon or rectum, expanding Aurobindo's biosimilar portfolio.